Skip to content
Back

Eva Murauer, PhD

Communication, PR & Grant Scouting

Research statement

During my scientific career my research work focused on the development of ex vivo gene replacement therapies, ex vivo and in vivo RNA trans-splicing therapies, as well as gene editing (CRISPR) strategies.

Personal interests

I love to discover the beauty of the mountains via hiking and mountain biking, and exploring the exciting under water nature through scuba diving.

Curriculum Vitae Eva Murauer

Professional Career

Since 2017
Communication, PR & Grant Scouting at the EB House Austria

Since 2017
European Project Manager at the University Hospital of Montpellier

2013 - 2017
Group leader of the Gene & Cell Therapy group, EB House Austria

2012-2013
Postdoc, Laboratory of Genetics of Rare Diseases, Montpellier, France

2008-2012
Postdoc, EB House Austria

 

Education

2008
PhD, Paris Lodron University Salzburg
"3' trans-splicing repair of the COL7A1 gene in dystrophic epidermolysis bullosa patients"
Research group: Univ.-Prof. Dr. Johann Bauer (EB House)

2005
MSc in Genetics and Biotechnology, Paris Lodron University Salzburg
"Isolation and characterization of EMPD specific single chain antibodies"
Research group: Univ.-Prof. Gernot Achatz

2002
BSc in Genetics and Molecular Biology, Paris Lodron University Salzburg

 

International Research Experience

2014 INSERM U844, Montpellier, France: Prof. Christian Jorgensen
2011/2012 Network of Excellence for Functional Biomaterials (NFB), NUIG, Galway, Ireland: Dr. Wenxin Wang
2009 Cutaneous Disease Modeling Unit, CIEMAT-CIBERER, Madrid, Spain: Dr. Larcher Laguzzi
2007 Laboratory of Cutaneous Biology and Physiopathology, INSERM U634, Nice, France: Prof. Guerrino Meneguzzi

 

Honours and Academic Awards

2017 Scientific award in gold from the Paracelsus Medical University, Salzburg
2013 Invited young scientist for the European Society for Dermatological Research (ESDR), Florence, Italy
2012 Sanofi Aventis prize for research in medicine
2011 Josef Kyrle travel grant from the Austrian Society for Dermatology and Venerology (OEGDV)
2011 Scientific award in silver from the Paracelsus Medical University, Salzburg
2010 UNILEVER Austrian Dermatology Award from the OEGDV
2010 ESDR Travel grant for the 40th Annual ESDR Meeting in Helsinki, Finland
2008 Isidor Neumann poster-price from the OEGDV within the annual meeting in Vienna
2008 Theodor-Koerner award from the Theodor Koerner Foundation Austria

 

Additional qualifications/training

2018 Course in Financial management of Horizon 2020 projects, EFMC, Frankfurt
2016 Course in Managment of R&D projects, Roland Gareis Consulting GmbH, Vienna
2016 Course in GCP - Good Clinical Practice, JSB Florence, trained in Salzburg
2016 Course in Clinical Studies Masterclass, Clinical Research Center Salzburg (CRSC)
2016 FFG (Austrian Research Promotion Agency) Training in Project Design and Proposal Writing in Horizon 2020, Vienna
2015 Course in Writing study protocols, CRCS
2015 Course in Applicaton to regulatory authorities and ethic committee, CRCS
2013 Course in Laboratory Animal Science: FELASA category B, Munich
2011 FWF (Austrian Science Fund) Coaching Workshop: Clinical Research, Vienna

Original articles

  1. Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, Tufa SF, Keene DR, Kiritsi D, Hainzl S, Murauer EM, Marinkovich MP, Platenburg G, Hausser I, Wally V, Ritsema T, Koller U, Haisma EM, Nyström A. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study. J Invest Dermatol
  2. Wimmer M, Zauner R, Ablinger M, Piñón-Hofbauer J, Guttmann-Gruber C, Reisenberger M, Lettner T, Niklas N, Proell J, Sajinovic M, De Souza P, Hainzl S, Kocher T, Murauer EM, Bauer JW, Strunk D, Reichelt J, Mellick AS, Wally V. A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas. Cell Commun Signal 2020;18:61
  3. Liemberger B, Piñón Hofbauer J, Wally V, Arzt C, Hainzl S, Kocher T, Murauer EM, Bauer JW, Reichelt J, Koller U. RNA Trans-Splicing Modulation via Antisense Molecule Interference. Int J Mol Sci 2018;19(3), 762.
  4. Kocher T, Peking P, Klausegger A, Murauer EM, Piñón Hofbauer J, Wally V, Lettner T, Hainzl S, Ablinger M, Bauer JW, Reichelt J, Koller U. Cut and Paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR/Cas9 nickases. Mol Ther 2017;25(11):2585-2598.
  5. Peking P, Koller U, Duarte B, Murillas R, Wolf S, Maetzig T, Rothe M, Kocher T, García M, Brachtl G, Schambach A, Larcher F, Reichelt J, Bauer JW, Murauer EM. An RNA-targeted therapy for dystrophic epidermolysis bullosa. Nucleic Acids Res. 2017;45(17):10259-10269.
  6. Hainzl S, Peking P, Kocher T, Murauer EM, Larcher F, Del Rio M, Duarte B, Steiner M, Klausegger A, Bauer JW, Reichelt J, Koller U. COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa. Mol Ther 2017;25(11):2573-2584.
  7. Bougé AL, Murauer E, Beyne E, Miro J, Mouly V, Varilh J, Taulan M, Koenig M, Claustres M, Tuffery-Giraud S (2016). Targeted RNA-Seq profiling of splicing pattern in the DMD gene: exons are mostly constitutively spliced in human skeletal muscle. Sci Rep 2017 Mar 28;7:45414.
  8. Bauer JW*, Koller J*, Murauer EM*, De Rosa L, Enzo E, Carulli S, Bondanza S, Recchia A, Muss W, Diem A, Mayr E, Schlager P, Gratz I, Pellegrini G, De Luca M. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J Invest Dermat. 2017; Mar;137(3):778-781. *joint first authorship
  9. Hüttner C, Murauer EM, Hainzl S, Kocher T, Neumayer A, Reichelt J, Bauer JW, Koller U. Designing Efficient Double RNA trans-Splicing Molecules for Targeted RNA Repair. Int J Mol Sci 2016;17(10).
  10. Tockner B, Kocher T, Hainzl S, Reichelt J, Bauer JW, Koller U*, Murauer EM*. Construction and validation of a RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations. Gene Ther 2016;23(11):775-784. *joint senior authorship
  11. Peking P, Koller U, Hainzl S, Kitzmueller S, Kocher T, Mayr E, Nystrom A, Lener T, Reichelt J, Bauer JW, Murauer EM. A gene gun-mediated non-viral RNA trans-splicing strategy for Col7a1 repair. Mol Ther Nucleic Acids 2016;5:e287.
  12. Cutlar L, Gao Y, Aeid A, Greiser U, Murauer EM, Zhou D, Wang W. A knot polymer mediated non-viral gene transfection for skin cells. Biomater Sci 2016; Jan;4(1):92-5.
  13. Koller U, Hainzl S, Kocher T, Hüttner C, Klausegger A, Gruber C, Mayr E, Wally V, Murauer EM. Trans-splicing improvement by the combined application of antisense strategies. Int J Mol Sci 2015;16(1):1179-1191.
  14. Gruber C, Koller U, Murauer EM, Hainzl S, Hüttner C, Kocher T, South AP, Hintner H, Bauer JW. The design and optimization of RNA trans-splicing molecules for skin cancer therapy. MolOncol 2013;7(6):1056-1068. 
  15. Wally V, Lettner T, Peking P, Peckl-Schmid D, Murauer EM, Hainzl S, Hintner H, Bauer JW. The Pathogenetic Role of Interleukin-1 Beta in Severe Epidermolysis Bullosa Simplex. J Invest Dermatol. 2013; Jul;133(7):1901-3.
  16. Murauer EM, Koller U, Hainzl S, Wally V, Bauer JW. A reporter-based screen to identify potent 3' trans-splicing molecules for endogenous RNA repair. Hum. Gene Ther. Methods 2013;24(1):19-27.
  17. Koller U, Wally V, Mitchell LG, Klausegger A, Murauer EM, Mayr E, Gruber C, Hainzl S, Hintner H, Bauer JW. A novel screening system improves genetic correction by internal exon replacement. Nucleic Acids Res 2011;39(16):e108.
  18. Gruber C, Gratz IK, Murauer EM, Mayr E, Koller U, Bruckner-Tuderman L, Meneguzzi G, Hintner H, Bauer JW. Spliceosome-mediated RNA trans-splicing facilitates targeted delivery of suicide genes to cancer cells. Mol. Cancer Ther. 2011;10(2):233-241. 
  19. Murauer EM, Gache Y, Gratz IK, Klausegger A, Muss W, Gruber C, Meneguzzi G, Hintner H, Bauer JW. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa. J Invest Dermat 2011; Jan;131(1):74-83.
  20. Wally V, Brunner B, Lettner T, Wagner M, Koller U, Trost A, Murauer EM, Hainzl S, Hintner H, Bauer JW. KRT14 mRNA reprogramming for dominant epidermolysis bullosa simplex. Hum Mol Genet 2010;19(23):4715-4725.

Reviews

  1. Peking P, Koller U, Murauer EM. Functional therapies for cutaneous wound repair in epidermolysis bullosa. Adv Drug Del Rev 2017;pii:S0169-409X(17)30306-X.
  2. Bornert O, Peking P, Bremer J, Koller U, van den Akker PC, Aartsma-Rus A, Pasmooij AM, Murauer EM, Nyström A. RNA-based therapies for genodermatoses. Exp Dermatol 2017;26(1):3-10.
  3. Murauer EM, Koller U, Pellegrini G, De Luca M, Bauer JW. Advances in Gene/Cell Therapy in Epidermolysis Bullosa. Keio J Med 2015;64(2):21-5.
  4. Koller U, Wally V, Bauer JW, Murauer EM. Considerations for a successful RNA trans-splicing repair of genetic disorders. Mol Ther Nucleic Acids 2014; 3: e157.
  5. Wally V*, Murauer EM*, Bauer JW. Spliceosome-mediated trans-splicing: the therapeutic cut and paste. J Invest Dermat. 2012; Aug;132(8):1959-66. doi: 10.1038/ jid.2012.101. Epub 2012 Apr 12. *joint first authorship

Book chapters

  1. Bauer JW, Murauer EM, Wally V, Koller U. RNA trans-splicing for genodermatoses. Methods Mol Biol 2013;961:441-455.
Back to main navigation